This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective cohort study with a historical control, which was carried out in two counties in New York State. A random sample of patients was selected for follow-up analysis and for the embedded experiment, in which patients were randomised to receive a guide (non-BQ arm) or the same guide plus BQ (BQ-arm). The length of followup was 4 to 6 months. The number of patients available in the follow-up analysis was 732. The numbers of patients included at the final assessment in the embedded study were 408 in the BQ group and 324 in the non-BQ group.
Analysis of effectiveness
The analysis of the clinical study was restricted to those individuals with available follow-up data. The outcome measures used in the analysis were response to promotions, quit attempts and quit rate. Response was evaluated by monitoring the volume of calls to the quitline in different periods (before, during and after the promotions). Quit rates were based on self-reported smoking behaviour and were defined as individuals not smoking and not having smoked a cigarette in the previous 7 days. A multiple regression analysis was carried out to estimate the relative risk for quitting amongst smokers who received the free NRT voucher compared with those who did not, adjusting for age, gender, race, type of insurance, and use of other quit methods since calling the quitline. The authors noted that the study participants were comparable to those who were not available at follow-up, but made no explicit comparisons of the baseline characteristics.
Effectiveness results
In the comparison between free NRT voucher and no intervention, the median number of calls per day to the quitline was 6.0 in the 2 weeks before the promotion, 148.0 during the implementation of the programme (25-fold increase), and 26.5 in the period after the promotion. It took 1 month after the promotion was discontinued to return to the prepromotion level of calls.
In the second comparison (guide versus guide plus BQ), the median number of calls per day was 7.0 in the period before the control advertisement was run, 14.0 during the running of this advertisement, and 27.5 in the period immediately after the newspaper advertisement offering BQ appeared. Thus, the guide advertisement increased the number of calls 2-fold, while the guide plus BQ advertisement increased the number of calls by about 4-fold.
In the first comparison, the proportion of quit attempts was 79% and the quit rate was 22% in individuals receiving free NRT.
Among individuals who redeemed their vouchers, 83% said they used the medications at least once, while 60% said they use the medications for a minimum of 14 days.
The quit rate was comparable for those who reported using either the nicotine patch or nicotine gum. It was much higher than the quit rate for those participants who said that they either did not redeem the voucher or did not use the medication (6%). The quit rate for the historical control group was 12%.
Multiple regression analysis showed that the relative risk for quitting with free NRT voucher over no intervention was
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1.77 (95% confidence interval: 1.17 to 2.68).
In the embedded study, 20% of individuals in the BQ group were not smoking at follow-up in comparison with 24% of those who did not receive BQ, a difference that was not statistically significant. Self-reported use of BQ was not associated with a higher quit rate.
Clinical conclusions
The effectiveness analysis showed that the press announcement of a programme giving away a voucher for a free 2-week supply of NRT was effective in improving the volume of calls to the quitline and the effective quit rate in comparison with other smoking cessation strategies. The use of newspaper advertisements for the quitline also increased the number of calls, although the increase was lower than for the free 2-week supply of NRT. Similar results were obtained for the guide and guide plus BQ strategies.
Measure of benefits used in the economic analysis
The benefit measure was the improvement in response (i.e. change in volumes of calls to the quitline). This was derived directly from the effectiveness analysis.
Direct costs
The perspective of the economic analysis was not explicitly reported. The analysis included the costs associated with medication and paid newspaper advertisements for the free 2-week supply of NRT, and BQ cigarette substitute and newspaper advertisements for the BQ strategy. The unit costs were reported for some categories of costs. Resource consumption was based on the actual number of patients enrolled in the study, as reported in the effectiveness study. The source of the costs was not explicitly stated. Discounting was not relevant as the costs were incurred during less than 2 years. The costs were gathered in 2003 and 2004 but the price year was not explicitly stated.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios were calculated in order to combine the costs and benefits of the alternative strategies over no intervention.
The incremental cost per extra call to the quitline was $11 with the free NRT voucher, $239 with the guide, and $80 with the guide plus BQ.
Authors' conclusions
Offering a free 2-week voucher for nicotine replacement therapy (NRT) was a cost-effective strategy for enhancing calls to quitlines in order to improve smoking quit rates in the USA.
CRD COMMENTARY -Selection of comparators
The rationale for the selection of the comparators was clear in that the new programmes based on advertisements were compared with strategies of no intervention. The programmes were described in detail and were implemented to induce smokers to call quitlines. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence was derived from a particular design in which a prospective cohort of individuals was compared with a historical control group on the one hand, whilst on the other hand, a sample of patients for which follow-up data were available was randomised to receive or not receive BQ. The authors did not provide a justification for the choice of this embedded design. The non-randomised part of the study was open to selection bias. Further, the substantial loss to follow-up may have adversely affected the degree to which the study sample was representative of the study population. The authors pointed out that non-participants were comparable with individuals who were available at follow-up, but baseline characteristics were not reported. However, statistical analyses were carried out to deal with potential baseline differences between the groups.
It was unclear whether the length of follow-up was appropriate. The impact of time differences between groups (especially with respect to the historical control) could have introduced some time-related bias. Another limitation of the analysis was the use of self-reported data, which were not validated using objective measures. Finally, the analysis was restricted to treatment completers only. These issues should be considered when assessing the validity of the clinical analysis.
Validity of estimate of measure of benefit
The summary benefit measure was specific to the intervention considered in the study. Thus, it will not be comparable with the benefits of other health care interventions; rather, it represents an intermediate measure. The use of a more widely used measure such as quit rate would have been interesting.
Validity of estimate of costs
The analysis of the costs was restricted to the costs associated with the advertisement programmes. Other costs borne, for example, by individuals such as out-of-pocket expenses for NRT outside the free supply period were not considered. The results of the analysis were presented selectively and were not extensively reported. The unit costs were given for some items, but it would probably be difficult to replicate the analysis in other settings as limited details of the method and conduct of the economic evaluation were provided. For example, the sources of the costs were not reported. The period during which the cost and resource use data were gathered was reported, but a single price year was not stated. In addition, statistical analyses of the costs were not performed and the cost estimates were specific to the study setting.
